Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panobacumab - Aridis Pharmaceuticals

Drug Profile

Panobacumab - Aridis Pharmaceuticals

Alternative Names: Aerumab; AERUMAB 11; AR 101 (anti-Pa mAb) - Aridis Pharmaceuticals; AR-101 - Aridis Pharmaceuticals; KBPA-101

Latest Information Update: 05 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Berna Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia; Ventilator associated pneumonia

Most Recent Events

  • 31 Dec 2020 Aridis Pharmaceuticals has patent protection for panobacumab in Canada, Europe, China, India, Israel, Japan, and USA
  • 15 Jun 2020 Aridis Pharmaceuticals plans a phase II/III trial for Nosocomial pneumonia in second half of 2020
  • 30 Sep 2019 Panobacumab licensed to the Serum Institute of India, in regions outside of USA, Europe, Canada, UK, China, Australia, New Zealand and Japan (9275697​)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top